Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9670.3273
Address
Level 11 Suite 2 385 Bourke Street Melbourne, Victoria (VIC) 3000
Description
Patrys Ltd. engages in the commercialization of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. Its pipeline includes PAT-DX1 antibody fragment, PAT-DX3 full sized antibody, and PAT-DX1-NP conjugated to nanoparticles. The company was founded by Daniel Devine on December 8, 2006 and is headquartered in South Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.01
Trade Value (12mth)
AU$1,151.00
1 week
50%
1 month
50%
YTD
-62.5%
1 year
-78.57%
All time high
0.62
EPS 3 yr Growth
-32.00%
EBITDA Margin
N/A
Operating Cashflow
-$2m
Free Cash Flow Return
-35.20%
ROIC
-68.70%
Interest Coverage
N/A
Quick Ratio
5.50
Shares on Issue (Fully Dilluted)
2056m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
08 July 25 |
Notification of cessation of securities - PAB
×
Notification of cessation of securities - PAB |
08 July 25 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
23 June 25 |
Initial Director's Interest Notices x2
×
Initial Director's Interest Notices x2 |
23 June 25 |
Final Director's Interest Notices x2
×
Final Director's Interest Notices x2 |
23 June 25 |
Notification of cessation of securities - PAB
×
Notification of cessation of securities - PAB |
18 June 25 |
Application for quotation of securities - PAB
×
Application for quotation of securities - PAB |
18 June 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
17 June 25 |
Deed of Release entered into with CEO
×
Deed of Release entered into with CEO |
17 June 25 |
Proposed issue of securities - PAB
×
Proposed issue of securities - PAB |
10 June 25 |
Successful Placement and Board Changes
×
Successful Placement and Board Changes |
10 June 25 |
Proposed issue of securities - PAB
×
Proposed issue of securities - PAB |
10 June 25 |
Proposed issue of securities - PAB
×
Proposed issue of securities - PAB |
10 June 25 |
Proposed issue of securities - PAB
×
Proposed issue of securities - PAB |
10 June 25 |
Proposed issue of securities - PAB
×
Proposed issue of securities - PAB |
10 June 25 |
Proposed issue of securities - PAB
×
Proposed issue of securities - PAB |
10 June 25 |
Reinstatement to Official Quotation
×
Reinstatement to Official Quotation |
03 June 25 |
Suspension from Quotation
×
Suspension from Quotation |
02 June 25 |
Change of Registered Office and Principal Place of Business
×
Change of Registered Office and Principal Place of Business |
30 May 25 |
Trading Halt
×
Trading Halt |
30 April 25 |
Appendix 4C - Quarterly - 31 March 2025
×
Appendix 4C - Quarterly - 31 March 2025 |
03 April 25 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
03 April 25 |
Notification of cessation of securities - PAB
×
Notification of cessation of securities - PAB |
31 March 25 |
Retirement of Non-Executive Director
×
Retirement of Non-Executive Director |
21 February 25 |
Appendix 4D - Half Year Accounts - 31 December 2024
×
Appendix 4D - Half Year Accounts - 31 December 2024 |
30 January 25 |
Appendix 4C - Quarterly - 31 December 2024
×
Appendix 4C - Quarterly - 31 December 2024 |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.